AR042140A1 - Composiciones para el tratamiento y profilaxis de infecciones por micobacterias - Google Patents

Composiciones para el tratamiento y profilaxis de infecciones por micobacterias

Info

Publication number
AR042140A1
AR042140A1 ARP030104344A ARP030104344A AR042140A1 AR 042140 A1 AR042140 A1 AR 042140A1 AR P030104344 A ARP030104344 A AR P030104344A AR P030104344 A ARP030104344 A AR P030104344A AR 042140 A1 AR042140 A1 AR 042140A1
Authority
AR
Argentina
Prior art keywords
compositions
activity against
mycobacteria
prophylaxis
treatment
Prior art date
Application number
ARP030104344A
Other languages
English (en)
Inventor
Dominguez Armando Acosta
Hernandez Yamile Lopez
Bourzac Juan Francisco Infante
Lahenz Armando Cadiz
Rodriguez Gustavo Falero
Gonzalez Victoriano Gustavo Sierra
Benitez Maximo Berto Martinez
Garcia San Miguel Maria Elena Sarmiento
Original Assignee
Inst Finlay Ct De Investigacio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Finlay Ct De Investigacio filed Critical Inst Finlay Ct De Investigacio
Publication of AR042140A1 publication Critical patent/AR042140A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Control de enfermedades infecciosas causadas por micobacterias, basados en la administración por vía de mucosas y otras vías de composiciones de anticuerpos para la profilaxis y terapéutica. Composiciones de anticuerpos humanos de clase IgG, IgA secretoria o mezclas de ambos con actividad específica contra antígenos de micobacteria para la prevención y tratamiento de infecciones causadas por este tipo de microorganismo. Dichas composiciones demostraron su capacidad de inhibir la infección por micobacterias "in vivo". Uso de dichas composiciones en combinación con drogas con actividad contra micobacterias. Reivindicación 1: Composición contra micobacterias porque contiene: a) anticuerpos humanos policlonales del tipo IgG o IgA secretoria o la mezcla de ambos con actividad contra componente de micobacterias; b) un vehículo farmacéutico adecuado; y c) eventualmente un componente seleccionado del grupo que comprende inmunomoduladores, cualquier combinación de cepas inactivas o atenuadas o lactoferrina.
ARP030104344A 2002-11-25 2003-11-25 Composiciones para el tratamiento y profilaxis de infecciones por micobacterias AR042140A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020275A CU23406A1 (es) 2002-11-25 2002-11-25 Composiciones contienendo anticuerpos humanos para el tratamiento y profiláxis de infecciones por micobacterias

Publications (1)

Publication Number Publication Date
AR042140A1 true AR042140A1 (es) 2005-06-08

Family

ID=32331941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104344A AR042140A1 (es) 2002-11-25 2003-11-25 Composiciones para el tratamiento y profilaxis de infecciones por micobacterias

Country Status (14)

Country Link
US (1) US20060222642A1 (es)
EP (1) EP1582218B1 (es)
CN (1) CN100579581C (es)
AR (1) AR042140A1 (es)
AU (1) AU2003285261A1 (es)
BR (1) BR0316558A (es)
CA (1) CA2507338A1 (es)
CU (1) CU23406A1 (es)
DE (1) DE60324466D1 (es)
MX (1) MXPA05005669A (es)
MY (1) MY143402A (es)
RU (1) RU2350352C2 (es)
WO (1) WO2004047865A1 (es)
ZA (1) ZA200504773B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664119A1 (en) 2003-09-08 2006-06-07 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
PL2821415T3 (pl) 2012-02-29 2021-07-05 Otsuka Pharmaceutical Co., Ltd. Przeciwciało przeciwko lipoarabinomannanowi i test immunologiczny do oznaczania zakażenia kwasoopornymi prątkami przy użyciu tego przeciwciała

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
US20010007660A1 (en) * 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same

Also Published As

Publication number Publication date
CN1756565A (zh) 2006-04-05
MY143402A (en) 2011-05-13
US20060222642A1 (en) 2006-10-05
CU23406A1 (es) 2009-08-04
CA2507338A1 (en) 2004-06-10
RU2350352C2 (ru) 2009-03-27
EP1582218A1 (en) 2005-10-05
MXPA05005669A (es) 2006-02-22
CN100579581C (zh) 2010-01-13
DE60324466D1 (de) 2008-12-11
RU2005119995A (ru) 2006-03-20
BR0316558A (pt) 2005-10-04
ZA200504773B (en) 2007-12-27
EP1582218B1 (en) 2008-10-29
WO2004047865A1 (es) 2004-06-10
AU2003285261A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
Carmichael et al. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
DK1326636T3 (da) Vaccinesammensætning
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
AR048912A1 (es) Inmunoglobulinas anti-nogo
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
AR057239A1 (es) Inmunoglobulinas
BRPI0508365A (pt) composições imunogênicas para chlamydia pneumoniae
AR107708A1 (es) Formulaciones de antagonista de il-6 y sus usos
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
US11208471B2 (en) Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
GT200100063A (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos
AR042140A1 (es) Composiciones para el tratamiento y profilaxis de infecciones por micobacterias
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR0212232A (pt) Agente antiinfluenza
RU2020112504A (ru) Композиции и способы для вызывания иммунного ответа против clostridium difficile
BRPI0516832A (pt) uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
AR115098A1 (es) Composiciones y métodos para la administración de aav

Legal Events

Date Code Title Description
FB Suspension of granting procedure